Aptevo Therapeutics Inc. (APVO) AI Stock Analysis

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company founded in 2016 and headquartered in Seattle, Washington. The company develops novel therapies that harness the immune system to treat various cancer types. Its lead candidate, APVO436, is a bispecific T-cell engaging antibody undergoing Phase 1b clinical trials for acute myelogenous leukemia and myelodysplastic syndrome. Aptevo's preclinical pipeline includes ALG.APV-527, a bispecific ADAPTIR candidate developed with Alligator Bioscience AB targeting 4-1BB and 5T4, APVO603 targeting 4-1BB and OX40, and APVO442, an ADAPTIR-FLEX bispecific candidate directed at PSMA-positive prostate cancer.

Aptevo's top line has fluctuated historically, rising from $23.1M in FY2018 to $32.4M in FY2019 before dropping to $4.3M in FY2020. Revenue rebounded to $12.3M in FY2021 and declined 74.7% to $3.1M in FY2022, representing a 5-year revenue CAGR of -26.6% from FY2017 to FY2022. Net income ranged from -$53.7M in FY2018 to $8.0M in FY2022, while operating margin in FY2022 was -919.7%. For the trailing twelve months ended June 30, 2026, revenue was $0, and quarterly revenue growth was -100.0% year-over-year. TTM earnings per share stood at $66.96, while return on equity was -420.3%.

As of June 30, 2026, Aptevo held $9.8M in cash and short-term investments against total debt of $4.2M, resulting in net cash of $5.6M. Total assets were $14.5M, shareholders' equity was $6.0M, the debt-to-equity ratio was 0.70, and the current ratio was 2.08. Free cash flow was -$21.1M in FY2022, alongside an operating cash flow of -$21.0M and R&D expense of $17.9M. In FY2025, the company paid dividends of $1.6M.

Aptevo's enterprise value is -$2.2M, reflecting a market capitalization of $2.9M. The stock trades at a price-to-sales ratio of 2.7x, below the 4.1x median of its US-listed Healthcare peers. Its forward price-to-earnings ratio is 3.9x compared to the peer median of 17.3x, and its EV-to-EBITDA multiple is 0.4x versus the peer median of 12.0x. Over the 1-year period through October 16, 2026, the stock fell 94.0%, while the S&P 500 (SPY) gained 16.8%. Over 5 years, the stock is down 100.0% compared to an 83.0% gain for the S&P 500.

Wall Street coverage tracked in the data includes 1 Strong Buy rating, 0 Buys, and 0 Hold or Sell ratings. The mean price target is $25.50, which is 1474.1% above the October 16, 2026 closing price of $1.62. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$16.02 on $0 in revenue. For the next fiscal year, 1 analyst estimates EPS of -$10.40 and revenue of $0. Aptevo beat EPS estimates in 2 of the last 4 quarters, with its next earnings date scheduled for November 5, 2026.

This page is an AI-written research summary of Aptevo Therapeutics Inc. (APVO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: APVO income statement, APVO balance sheet, APVO key metrics, APVO analyst forecast, APVO chart. See the APVO stock overview for the latest quote and news.